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Abstract
Background. Vitamin D deficiency has been associated with both
poor bone health and mental ill-health. More recently, a number of
studies have found individuals with depressive symptoms tend to have
reduced bone mineral density. To explore the interrelationships
between vitamin D status, bone mineral density and mental-ill health
we are assessing a range of clinical, behavioural and lifestyle factors
in young women (Part A of the Safe-D study).
Design and methods. Part A of the Safe-D study is a cross-sectional
study aiming to recruit 468 young females aged 16-25 years living in
Victoria, Australia, through Facebook advertising. Participants are
required to complete an extensive, online questionnaire, wear an
ultra-violet dosimeter for 14 consecutive days and attend a study site
visit. Outcome measures include areal bone mineral measures at the
lumbar spine, total hip and whole body, as well as soft tissue composi-
tion using dual energy x-ray absorptiometry. Trabecular and cortical
volumetric bone density at the tibia is measured using peripheral
quantitative computed tomography. Other tests include serum 25-
hydroxyvitamin D, serum biochemistry and a range of health markers.
Details of mood disorder/s and depressive and anxiety symptoms are
obtained by self-report. Cutaneous melanin density is measured by
spectrophotometry. 
Expected impact. The findings of this cross-sectional study will have
implications for health promotion in young women and for clinical
care of those with vitamin D deficiency and/or mental ill-health.
Optimising both vitamin D status and mental health may protect
against poor bone health and fractures in later life.
Introduction
Vitamin D deficiency, osteoporosis and depression are all major
public health issues and contribute substantially to the global burden
of disease. These conditions are most likely inter-related although the
aetiology of the relationship is not currently well understood. 
Vitamin D deficiency, defined by the Australian and New Zealand
Bone and Mineral Society as serum 25-hydroxyvitamin D (25OHD) lev-
els of <50 nmol/L, is emerging as a global, public health issue in all age
groups.1 In Australia, vitamin D deficiency affects 1 in 3 adults and is
increasingly common in females, with more than 50% of Australian
women having insufficient serum vitamin D in Winter-Spring. 
Vitamin D is essential in achieving optimal musculoskeletal health.
In children, long-term vitamin D deficiency can cause growth retarda-
tion and deformities in the skeleton. In adults, chronic vitamin D defi-
ciency can lead to osteomalacia (defective bone mineralisation) and
osteoporosis (a skeletal disease characterised by low bone mass and a
subsequent increase in fracture risk). Each year there are an estimat-
ed 9.0 million fractures associated with osteoporosis globally resulting
in significant mortality, disability and economic burden. The total
health-care expenditure on musculoskeletal conditions in Australia in
2008-09 was $5.7 billion. In 2012, the national total direct and indirect
costs associated with osteopenia and osteoporosis in Australia was
AUD 2.75 billion: these costs will only increase with population ageing.
Vitamin D deficiency is also associated with a number of poor health
outcomes including an increase the risk of chronic health conditions
such as diabetes, cardiovascular disease, some cancers, autoimmune
diseases, infection and adverse mental health outcomes. Collectively,
these health conditions affect millions of Australians, potentially lead-
ing to substantial reductions in vitality, economic loss and mortality.
Similar to vitamin D deficiency, mental disorders are also common
worldwide. Worldwide prevalence estimates for mood disorders, such
as depression, are between 3.3 and 21.4%, while those for anxiety dis-
orders are between 4.8 and 31.0%. In Australia, almost half of the pop-
ulation aged 16-85 years (45%) are estimated to have a mental disor-
der at some point in their lifetime. Females are more likely to experi-
Significance for public health
Vitamin D deficiency, depression and osteoporosis are all major public
health issues. Vitamin D deficiency has been associated with both reduced
bone mineral density and depressive symptoms. Moreover, cohort studies
have found that subjects with depression have lower bone mineral density
when compared to healthy controls. Early adulthood is a critical time in
young woman's lives as their independence, behaviours and lifestyle choices
are established. These choices made as a young adult lay down the founda-
tion for future health trajectories for not only for themselves but also for
their potential partners and families. Addressing vitamin D deficiency, poor
bone health and mental ill-health at a younger age may ultimately improve
their wellbeing, productivity and long-term health outcomes. This study is of
particular significance as the interplay between vitamin D, depression and
bone health is currently uncertain and such knowledge is crucial for under-
standing, prevention and treatment of these conditions. 
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ence a 12-month mental disorder than males and the prevalence of 12-
month mental disorders is highest in young adults aged 16-24 years.
Depression and anxiety disorders also account for most disability-
adjusted life years globally. Depression, in particular, contributes most
of the non-fatal burden of mental and substance use disorders. It is
characterised by sadness, irritability and anhedonia, in addition to a
range of psychophysiological changes including sleep disturbance,
weight change, feelings of worthlessness and suicidal ideation.
Although the exact causes of depression are unknown it is likely to be
the result of complex interactions between social, psychological and
biological factors, one of which may be vitamin D deficiency. 
The vitamin D receptor is found in numerous regions of the human
brain, including the temporal, orbital and cingulate cortex, in the thal-
amus, in the accumbens nuclei, parts of the stria terminalis and amyg-
dala and throughout the olfactory system. Vitamin D is suggested to
have a number of functions within the human brain including the reg-
ulation of neurotrophic factors such as nerve growth factor, neuropro-
tection, neuroplasticity and modulating inflammation. The identifica-
tion of vitamin D-responsive elements in the promoter region of sero-
tonin receptors and tryptophan hydroxylase makes the link between
mental disorders and vitamin D deficiency biologically plausible. 
Animal models have shown that vitamin D can protect against
methamphetamine-induced depletion of dopamine and serotonin, neu-
rotransmitters that both play a role in depression. There are a number
of cross-sectional studies suggesting a link between serum 25OHD and
depression. Anglin et al. compared 10 cross-sectional studies and
demonstrated a strong association between vitamin D levels and
increased risk of depression (OR=1.3, 95%CI: 1.0-1.7).2 Similarly, a
meta-analysis of cross-sectional and cohort studies found an inverse
association between serum 25OHD levels and the risk of depression.3
A recent prospective, nested, case-control study in 495 US military sui-
cide cases found that individuals with lower 25OHD levels had in-
creased risk of suicide when compared to matched controls after
adjustements for season of serum collection.4 Reviews of randomised
controlled trials investigating the effects of vitamin D supplementation
on depressive symptoms suggest that supplementation may only be
beneficial in patients presenting with clinical depression but further,
high-quality research with appropriate doses and outcome measures
are needed to address the issue. 
Although depression is not currently considered an established risk
factor for osteoporosis, there is growing evidence that those with
depression may be at greater risk of reduced bone mineral density
(BMD). The strength of the association varies between studies, with
one study finding patients with major depression had a 15% deficit in
lumbar spine BMD on average, when compared to healthy controls,5
while others have found no association between depression diagnosis
or symptoms and BMD.6,7 In a meta-analysis of studies exploring the
relationship between depression and reduced BMD, Cizza et al.8 found
that BMD was reduced in subjects with depression at each skeletal site
measured when compared to control subjects. In depressed patients,
BMD was 4.7% lower at lumbar spine (95%CI −7.3% to −2.2%, P<0.001;
n=16 studies), 7.3% lower at femoral neck (95%CI −10.7% to −3.9%;
P<0.001; n=8 studies) and 3.5% lower at total hip (95%CI −5.7% to
−1.4%, P<0.001; n=13 studies).8 It is most likely that a link exists
between depression and osteoporosis mediated by factors such as cor-
tisol, inflammatory markers and vitamin D. In patients who have sus-
tained osteoporotic fractures it is possible that this link may be bidirec-
tional in nature. Behavioural factors such as physical activity, smoking,
alcohol and drug use may also mediate the relationship. 
Taking into consideration the high prevalence of both depression
and vitamin D deficiency in young women, it is clinically relevant to
explore the possible links between these conditions and poor bone
health together with lifestyle, behavioural and clinical factors that may
mediate such associations. By looking at the strength and clustering of
associations, this investigation may provide new insights into the pos-
sible causal relationships between these problems and thereby help
efforts to reduce the risk of fracture in adult life. Hence, the aim of the
study is to explore the interrelationships between vitamin D status,
depression and osteopenia/osteoporosis in a cohort of young women. 
Design and methods
The study protocol was approved by Melbourne Health Human
Research and Ethics Committee, Melbourne Health, Victoria, Australia
(project number 2013.007). The study is being carried out in accor-
dance with the National Statement on Ethical Conduct in Research
Involving Humans (2007) produced by the National Health and Medical
Research Council of Australia. The Safe-D study is funded by National
Health and Medical Research Council (NHMRC) project grant
APP1049065. Study design
The Safe-D study builds on the Young Female Health Initiative
(YFHI) pilot study exploring health and well-being in young women.9
The Safe-D study comprises two parts: part A is a cross-sectional study
of young women to explore the association between vitamin D status
and a range of important clinical health indices; part B is a randomised
controlled trial to assess the effectiveness of an mHealth-based lifestyle
intervention to improve vitamin D status and related health in young
women with vitamin D levels ranging from 25-75 nmol/L. This manu-
script focuses on the study protocol for part A of the Safe-D study. Recruitment
Young women aged 16-25 years currently living in Victoria,
Australia, are recruited through a Facebook advertising campaign.9
Potential participants who click on the Safe-D study Facebook adver-
tisement are redirected to a secure study website (www.safedstudy.
org) where they are able to submit an expression of interest (EOI).
Subjects who submit an EOI are contacted by telephone and given an
overview of the study and their eligibility to participate is  assessed.
Young women under the age of 18 years are taken through a mature
minor assessment by a study team member.9 Pregnant or breast feed-
ing women are excluded from the study. Participants are recruited into
the study if they are able to provide both verbal and written consent to
complete all three study components; an online questionnaire, wear a
sun monitoring device and attend a study site visit. Study package
Each participant is sent a study package containing a Patient
Information and Consent Form (PICF) used to obtain written consent.
Included in the package is an ultra-violet (UV) dosimeter which partic-
ipants are asked to wear on their wrist for 14 consecutive days. The UV
dosimeters, used to measure personal UV exposure, were developed at
the National Institute of Water and Atmospheric Research in New
Zealand (manufactured by Scienterra, New Zealand) and have been set
up and calibrated by the Australian Radiation Protection and Nuclear
Safety Agency (ARPANSA, Melbourne, Australia). UV dosimeter data
are downloaded and analysed to calculate average daily standard ery-
themal dose (SED) for each participant. Online questionnaire
Participants are emailed links to an extensive questionnaire online
which takes 1.5 to 2 hours to complete. The questionnaire is divided
into 6 modules which participants can chose to complete in one sitting
or one module at a time over the space of a week. Participants are
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asked questions regarding their medical history, including a diagnosis
of depression or any other mental disorders, including age of diagnosis
(if applicable). Participants may also report antidepressant use when
asked about prescription medications used in the previous week. The
Patient Health Questionnaire depression scale (PHQ-9) is used to
assess depressive symptoms. It scores each of the nine Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria as
0 (not at all) to 3 (nearly every day), to establish a depressive disorder
diagnosis and grade its severity. The 7-item Generalised Anxiety
Disorder Scale (GAD-7) is used to assess the probable cases of
Generalised Anxiety Disorder (GAD) and measure symptom severity.
Similar to the PHQ-9, it scales DSM criteria for GAD from 0 to 3 to give
an overall score. Increasing scores are strongly associated with func-
tional impairment and disability days. Other relevant information
being collected in the questionnaire includes: race, age at menarche,
hormonal contraceptive use, physical activity, smoking, alcohol use,
sun exposure, calcium intake and vitamin D intake. Study visit
Participants attend a 2-hour study site visit at the Royal Melbourne
Hospital, Parkville, Victoria, Australia, that consists of:Bone densitometry
Areal BMD is measured using dual energy X-ray absorptiometry
(DXA) (QDR 4500A densitometer, Hologic Inc., Bedford, USA). Scans
are analysed with QDR software version 9.1D. Areal BMD and bone
mineral content (BMC) are measured at the lumbar spine (L1-L4), total
hip and total body. Non-bone lean mass (kg), fat mass (kg) and percent
body fat are also assessed. Peripheral quantitative computed tomogra-
phy (pQCT) (XCT 3000, Stratec Medizintechnik GmbH, Pforzheim,
Germany) is performed at the distal tibia (at the 4% site of the tibial
length proximal to the distal end plate) and at the tibial shaft (at the
66% site) of the non-dominant leg. Scans are analysed with software
version 5.50 to assess bone parameters including BMC, volumetric
BMD, total bone area (toA), cortical area (coA), cortical thickness
(coTh), polar stress-strain index (SSIp) and bone strength index (BSI).
Muscle cross-sectional area (MCSA) is also measured. Anthropometry 
A wall-mounted Holtain stadiometer (Holtain Ltd., Crymych, Dyed,
UK) is used to measure height to the nearest 1mm. A mechanical beam
balance scale (Continental Scale, Bridgeview, IL, USA) is used to meas-
ure body weight to the nearest 0.1 kg. Body mass index (BMI) is calcu-
lated from these measurements (weight in kilograms divided by height
in metres squared) and categorised into underweight, overweight or
obese according to World Health Organisation (WHO) criteria. Biochemical assays
Serum levels of 25OHD (25OHD3 plus 25OHD2) is measured using
liquid chromatography tandem mass spectrometry (LC-MS/MS) at
VivoPharm Laboratories (Melbourne, Australia). The D2 metabolite has
a lower detection limit of 5.12 nM while D3 is 6.94nM. The intraassay
coefficient of variation (CV) is 4.9% for total 25OHD while the interas-
say CV for 25OHD2 and 25OHD3 is 3.7% and 1.6% respectively. 
Bone turnover markers C-terminal telopeptide of type I collagen
(CTX) and procollagen type 1 amino-terminal peptide (P1NP) as well as
oestradiol are measured using the Roche Cobas e411 automated
analyser (Roche Diagnostics GmbH, Mannheim, Germany). Serum bio-
chemistry is measured using an Abbott ARCHITECT c16000 integrated
system (Abbott Diagnostics, Abbott Park, IL, USA). Parathyroid hor-
mone (PTH), testosterone, sex hormone bind globulin (SHBG) and pro-
lactin are measured using an Abbott ARCHITECT i2000 SR immunoas-
say connected to a FlexLab track (Abbott Diagnostics). 
Spectrophotometry
Cutaneous melanin density (i.e. skin colour) is measured using a
2500d Konica Minolta portable spectrophotometer (Osaka, Japan) cou-
pled with a skin analysis program (CM-SA, Konica Minolta Sensing
Inc., Osaka, Japan). Melanin density is assessed at the inner, upper
arm (i.e. UV-unexposed region) and both the back of the hand and the
cheek (i.e. UV-exposed regions). Three measurements are taken at
each region. Spectrophotometer data are then exported from the soft-
ware and the average of the triplicates is calculated to give a final
melanin density for each location. Sample size and power
It is necessary for the sample size for part A of the Safe-D project to
provide sufficient eligible participants to recruit adequate numbers for
part B of the study. Based on assumptions regarding increases in
serum 25OHD with vitamin D supplementation and taking into account
study attrition rates, a recruitment target of 468 participants was set
for part A. This sample size gives 80% power at 5% significance level to
detect small-medium effect sizes (Cohen’s d=0.25-0.3) in outcome
measures, comparing participants with serum 25OHD above and below
the mean. This effect size corresponds to a 4% difference in lumbar
spine and total hip BMD (standard deviation 13%) and a 2.5% differ-
ence in whole body BMD (standard deviation 9%).10
Discussion
Adolescence and young adulthood are crucial life stages, during
which the foundations for a woman’s health across her lifespan are laid
down. Ensuring optimal health during this time is extremely important
in the prevention of a range of chronic health conditions, including
obesity, diabetes, cancer and cardiovascular disease. To prevent muscu-
loskeletal conditions such as osteoporosis and related fractures it is
crucial to achieve optimal peak bone mass and offset bone loss in later
life, whether this is by maintaining adequate vitamin D levels, improv-
ing calcium intake or perhaps the treatment of mental ill-health. 
This study will provide insight into the prevalence of depressive
symptoms and osteopenia/osteoporosis in young Australian women and
may shed light on some of the lifestyle, behavioural and clinical char-
acteristics that may put women at risk of poor bone health in adult-
hood. The aetiology of the relationship between bone mineral density
and mental health, more specifically depression, and the direction of
the link between these health domains is unclear at present but it likely
to be multifactorial in nature (Figure 1). Few studies have examined
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Figure 1. The potential relationships between vitamin D, bone
health and mental health.
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whether vitamin D is a common mediator between depression and
reduced BMD.5,6,11-13 In those that have been tested for vitamin D, out-
come measures that may affect an individual’s 25OHD levels such as
skin colour, sun exposure, physical activity and diet were not fully
examined.7,14 The Safe-D study is a comprehensive, multi-factorial
study which is well-placed to enhance understanding of the links
between mood, vitamin D and BMD in this currently under-represented
demographic.
Previous studies investigating mental disorders and reduced BMD
have suggested that mediating factors such as cortisol, serotonin or
inflammatory cytokines (e.g. interleukin-6, interleukin-1, tumour
necrosis factor alpha) may provide a link between these problems.15
The Safe-D study aims to also investigate a range of lifestyle factors
which may affect the interrelationships between these health problems
including physical activity, diet, smoking habits, alcohol and drug use.
Improving health behaviours in young women will reduce the risk of
chronic health problems in later life. 
Current guidelines do not list depression as a risk factor for osteo-
porosis, although individuals taking selective serotonin reuptake
inhibitors are listed as having a possible increased risk. Previous liter-
ature provides evidence that individuals with depression have greater
reductions in BMD suggesting a mental health diagnosis such as
depression should be taken into account when assessing an individ-
ual’s risk of osteoporosis. By looking at the strength and clustering of
associations between vitamin D deficiency, BMD and depression, the
study may provide new insights into the determinants of vitamin D sta-
tus and health outcomes in young women, as well as the possible
causal relationships between these problems. If it is clear that a num-
ber of modifiable lifestyle and behaviour traits are associated with vita-
min D deficiency, mental ill-health and/or poor bone health, these may
be highlighted in national health promotion strategies. Public health
messages may include encouraging safe sun exposure to improve vita-
min D levels or promoting participation in physical activity. Promoting
preventative behaviours and highlighting their importance to young
women will put them in the best position to transition into adulthood
at their healthiest. With vitamin D deficiency looming as a major public
health issues it is crucial we gain a better understanding of vitamin D
status, its determinants and its effect on biologically complex condi-
tions such as osteoporosis and depression. 
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